Currently several @entity4149 kinase inhibitors (TKIs) are approved for treatment of @entity1860 ( @entity1860 ). Our goal was to identify the optimal sequential treatment strategy in terms of effectiveness and cost-effectiveness for @entity1860 @entity1 within the US health care context. We evaluated 18 treatment strategies regarding survival, quality-adjusted survival, and costs. For model parameters, the literature data, expert surveys, registry data, and economic databases were used. Evaluated strategies included @entity2213 , @entity8947 , @entity10542 , @entity31438 , @entity34679 , @entity8 ( @entity8 ), and chemotherapy. We developed a Markov state-transition model, which was analyzed as a cohort simulation over a lifelong time horizon with a third-party payer perspective and discount rate of 3%. Remaining life expectancies ranged from 5.4 years (3.9 quality-adjusted life years (QALYs)) for chemotherapy treatment without TKI to 14.4 years (11.1   QALYs) for @entity10542 > @entity8947 > chemotherapy/ @entity8 . In the economic evaluation, @entity2213 > chemotherapy/ @entity8 resulted in an incremental cost-utility ratio (ICUR) of  171,700/QALY compared to chemotherapy without TKI. @entity2213 > @entity10542 > chemotherapy/ @entity8 yielded an ICUR of  253,500/QALY compared to @entity2213 > chemotherapy/ @entity8 . @entity10542 > @entity8947 > chemotherapy/ @entity8 yielded an ICUR of  445,100/QALY compared to @entity2213 > @entity10542 > chemotherapy/ @entity8 . All remaining strategies were excluded due to dominance of the clinically superior strategies. Based on our analysis and current treatment guidelines, @entity2213 > @entity10542 > chemotherapy/ @entity8 and @entity10542 > @entity8947 > chemotherapy/ @entity8 can be considered cost-effective for @entity1 with @entity1860 , depending on willingness-to-pay.

Effectiveness and Cost-Effectiveness of Sequential Treatment of XXXX with @entity1860 in the United States: A Decision Analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['stem-cell transplantation', 'SCT'] @entity8947 :: ('MESH:C488369', 'Chemical') :: ['dasatinib'] @entity34679 :: ('MESH:C545373', 'Chemical') :: ['ponatinib'] @entity31438 :: ('MESH:C471992', 'Chemical') :: ['bosutinib'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia'] @entity10542 :: ('MESH:C498826', 'Chemical') :: ['Nilotinib', 'nilotinib'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib', 'Imatinib']
@entity1 :: (9606,Species) :: ['Patients']
